Global Migraine Market Growth (Status and Outlook) 2023-2029

Global Migraine Market Growth (Status and Outlook) 2023-2029

A migraine is a primary headache disorder characterized by recurrent headaches that are moderate to severe. Typically, the headaches affect one half of the head, are pulsating in nature, and last from two to 72 hours. Associated symptoms may include nausea, vomiting, and sensitivity to light, sound, or smell. The pain is generally made worse by physical activity.

LPI (LP Information)' newest research report, the “Migraine Industry Forecast” looks at past sales and reviews total world Migraine sales in 2022, providing a comprehensive analysis by region and market sector of projected Migraine sales for 2023 through 2029. With Migraine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Migraine industry.

This Insight Report provides a comprehensive analysis of the global Migraine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Migraine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Migraine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Migraine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Migraine.

The global Migraine market size is projected to grow from US$ 5037.6 million in 2022 to US$ 8921 million in 2029; it is expected to grow at a CAGR of 8.5% from 2023 to 2029.

Globally, approximately 15% of people are affected by migraines. It most often starts at puberty and is worst during middle age. As of 2016 migraines is one of the most common causes of disability.

This report presents a comprehensive overview, market shares, and growth opportunities of Migraine market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Oral
Injectable
Nasal Sprays
Others

Segmentation by application
Hospitals
Clinics
Home Care

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
GlaxoSmithKline
Allergan
Amgen
Eli Lilly
Teva Pharma
Biohaven Pharma
Abbott Laboratories
Johnson & Johnson
Valeant Pharma

Please note: The report will take approximately 2 business days to prepare and deliver.